GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BMS820132 | compound 31 [PMID: 35179904]
Compound class:
Synthetic organic
Comment: BMS-820132 is an investigational oral glucokinase (hexokinase 4) partial activator that was designed for potential to treat type 2 diabetes mellitus (T2DM) [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| BMS-820132 was progressed to Phase 1 clinical evaluation. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01105429 | Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes | Phase 1 Interventional | Bristol-Myers Squibb | ||
| NCT01290575 | Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes | Phase 1 Interventional | Bristol-Myers Squibb | ||